CoChat

Lixisenatide, a novel GLP‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus

Bolli, G. B., Owens, D. R. · 2014 · Diabetes, Obesity and Metabolism
Cited by 36

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Recent advances in therapies for the treatment of type 2 diabetes mellitus (T2DM) have led to the development of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), which, unlike insulin and sulphonylurea, are effective, with a low risk of hypoglycaemia. Lixisenatide is recommended as a once‐daily GLP‐1 RA for the treatment of T2DM. In persons with T2DM, lixisenatide 20 µg once‐daily given by bolus subcutaneous injection improves insulin secretion and suppresses glucagon secretion in a glucose‐dependent manner. Compared with the longer‐acting GLP‐1 RA liraglutide, lixisenatide achieved a significantly greater reduction in postprandial plasma glucose (PPG) during a standardized test breakfast in persons with T2DM otherwise insufficiently controlled on metformin alone. This is primarily due to the greater inhibition of gastric motility by lixisenatide compared with liraglutide. The efficacy and safety of lixisenatide was evaluated across a spectrum of T2DM in a series of phase III, randomized, placebo‐controlled trials known as the GetGoal programme. Lixisenatide monotherapy or as add‐on to oral antidiabetic agents or basal insulin achieved significant reductions in glycated haemoglobin, PPG and fasting plasma glucose, with either weight loss or no weight gain. The most frequent adverse events were gastrointestinal and transient in nature. Lixisenatide provides an easy, once‐daily, single‐dose, add‐on treatment to oral antidiabetic agents or basal insulin for the management of T2DM, with little or no increased risk of hypoglycaemia and a potential beneficial effect on body weight.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12253

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 36

  1. 10.2337/dc12-0413 · DOI · Paper page
  2. 10.1111/j.1463-1326.2008.00881.x · DOI · Paper page
  3. 10.1210/jc.85.10.3575 · DOI · Paper page
  4. 10.1210/endo.134.5.8156917 · doi:10.1210/endo.134.5.8156917 · Paper page
  5. 10.1111/j.1463-1326.2012.01560.x · DOI · Paper page
  6. 10.1152/ajpendo.00545.2003 · DOI · Paper page
  7. Komatsu R, 1989, Glucagonostatic and insulinotropic action of glucagonlike peptide I‐(7–36)‐amide, Diabetes, 38, 902, 10.2337/diab.38.7.902 · DOI · Paper page
  8. 10.1210/jc.81.1.327 · DOI · Paper page
  9. 10.1093/ajcn/68.3.525 · DOI · Paper page
  10. 10.1002/dmrr.1202 · DOI · Paper page
  11. 10.1016/S1262-3636(08)73398-6 · DOI · Paper page
  12. 10.1152/physrev.00034.2006 · DOI · Paper page
  13. 10.2165/00126839-200708030-00002 · DOI
  14. 10.1016/j.numecd.2008.08.002 · DOI
  15. 10.5414/CP201462 · DOI · Paper page
  16. 10.2337/dc10-1393 · DOI · Paper page
  17. American Diabetes Association, 2012, Introduction: the American Diabetes Association's (ADA) evidence‐based practice guidelines, standards, and related recommendations and documents for diabetes care, Diabetes Care, 35, S1
  18. 10.1016/S0021-9258(19)36565-2 · DOI · Paper page
  19. 10.1016/j.beem.2009.03.008 · DOI
  20. 10.1111/j.1463-1326.2012.01557.x · DOI · Paper page
  21. 10.2337/dc12-2462 · DOI · Paper page
  22. 10.1111/j.1463-1326.2012.01618.x · DOI · Paper page
  23. 10.2337/dc09-2191 · DOI · Paper page
  24. 10.4158/EP.13.5.444 · DOI
  25. 10.1055/s-2008-1042426 · DOI · Paper page
  26. Ratner R, 2011, Efficacy and safety of lixisenatide once daily versus placebo in patients with T2DM insufficiently controlled on sulfonylurea±metformin (GetGoal‐S) [Abstract], Diabetologia, 54, A785
  27. 10.1016/j.regpep.2013.04.001 · DOI · Paper page
  28. Becker R, 2012, Augmentation of 1st‐phase insulin release with lixisenatide in non‐diabetic subjects (Abstract 1149‐P), Diabetes, 61, A212
  29. Becker R, 2012, Restitution of glucose disposition with lixisenatide in T2DM subjects (Abstract 1081‐P), Diabetes, 61, A212
  30. 10.1111/j.1464-5491.2010.03020.x · DOI · Paper page
  31. 10.1111/dom.12076 · DOI · Paper page
  32. 10.2337/dc06-2593 · DOI · Paper page
  33. 10.1111/dom.12121 · DOI · Paper page
  34. Raccah D, 2012, Efficacy and safety of lixisenatide in elderly (≥65 yr) and very elderly (≥75 yr) patients with type 2 diabetes: an analysis from the GetGoal Phase 3 program (Abstract 972‐P), Diabetes, 61, A212
  35. 10.2337/dc08-9025 · DOI · Paper page
  36. 10.1007/BF00265086 · DOI · Paper page

Cited by

See all 36

Metadata

Authors
Bolli, G. B., & Owens, D. R.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2014-01-20
Volume
16
Issue
7
Pages
588-601
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W1978569902
Cited by
36
References
27
FWCI
3.07
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Lixisenatide, a novel GLP‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus. https://app.cochat.ai/papers/10.1111/dom.12253
The paper
Bolli, G. B., & Owens, D. R. (2014). Lixisenatide, a novel GLP‐1 receptor agonist: efficacy, safety and clinical implications for type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12253

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.